Latest Regulatory Approvals News

IDP Education has rejected a second, higher takeover proposal from Blackstone, saying the $2.50-per-share offer fails to capture the value of its platform and transformation program. The confidential, non-binding proposal leaves open the question of whether Blackstone will return with a revised bid.

Booster Innovation Fund has invested $200,000 in TheiaNova, a University of Auckland spinout developing a self-administered eye drop for keratoconus. The seed-stage bet accounts for 0.76% of BIF’s portfolio, keeping the exposure modest while adding an early biotechnology asset.

European Lithium has dispatched the scheme booklet for its proposed merger with NASDAQ-listed Critical Metals Corp., putting shareholders and optionholders on the path to votes on 22 October. The transaction remains conditional on securityholder, Court and regulatory approvals, with implementation targeted for 5 November.

Bounty Oil & Gas NL (ASX:BUY) is pursuing a 2,322 km² deepwater exploration block offshore Liberia, backed by a $3.55 million placement and major vendor-linked securities. The opportunity remains conditional: the block has no executed production sharing contract, no independent resource estimate and has not yet been reviewed directly by Bounty.

Microba shareholders would own about 67% of an enlarged Genetic Signatures under a proposed all-scrip merger valued at approximately A$51 million. The deal combines roughly A$29.6 million of FY2026 revenue and identifies up to A$3 million in potential annual cost synergies, but remains subject to a long list of approvals.

Rhythm Biosciences has completed the first phase of transferring its ColoSTAT blood test to an independent NHS laboratory in England. The milestone supports its international laboratory-partnership strategy, but clinical validation and NHS adoption remain ahead.

Capstone Copper will sell its Cozamin copper-silver-zinc-lead mine in Mexico to Luca Mining for up to US$385 million, including US$275 million in upfront cash. The proposed divestment is designed to strengthen Capstone’s balance sheet and redirect capital towards its growth pipeline.

Cygnus has cleared the remaining conditions tied to its options and share rights, but Central Asia Metals now expects Kazakhstan approval after the scheduled 23 September court date. The proposed takeover timetable will be pushed back, with approval currently expected by 12 October.

G11 Resources has designed three drill holes to test the Northeast Pyrite copper-gold target in western Tasmania, close to the Great Lyell Fault and Mt Lyell deposits. The program may receive up to $120,000 in Tasmanian Government co-funding, but the geological case still rests heavily on unverified historical data.

ReNerve has converted regulatory approvals into its first commercial NervAlign Nerve Cuff surgeries in Hong Kong and Malaysia, expanding activity to seven jurisdictions. The milestones arrive as FY26 sales climbed 88% to $510,357 and the company builds out its US distribution network.

Orthocell has recorded the first commercial sales of its Remplir nerve repair product in Thailand, opening a new market estimated at US$84 million. The launch gives the company another distributor-led growth channel, although near-term sales are expected to remain modest.

Ingenia Communities has rejected Warburg Pincus’s revised $5.05 per stapled security proposal, saying the offer substantially undervalues the group. The board remains open to a higher-value approach, leaving the takeover discussion unresolved.